Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1NETWORK 1

Study Type

Observational 3Interventional 2

Sponsor

Cancer Type

Genitourinary 5

Conditions

Neoplasms 3210Carcinoma, Non-Small-Cell Lung 2721Breast Neoplasms 2547Colorectal Neoplasms 1454Prostatic Neoplasms 1303Neoplasm Metastasis 1292Multiple Myeloma 1109Melanoma 1101Ovarian Neoplasms 1001Lung Neoplasms 941Recurrence 921Leukemia, Myeloid, Acute 876Pancreatic Neoplasms 830Lymphoma, Non-Hodgkin 766Lymphoma 713Stomach Neoplasms 691Carcinoma, Renal Cell 658Carcinoma, Hepatocellular 645Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 546Lymphoma, Follicular 515Head and Neck Neoplasms 488Glioblastoma 472Small Cell Lung Carcinoma 444Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 433Advanced Solid Tumors 430Leukemia 426Uterine Cervical Neoplasms 418Urinary Bladder Neoplasms 405

Interventions

enzalutamide 2darolutamide 2Docetaxel 2Androgen Antagonists 2apalutamide 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Hormone-sensitive Prostate Cancer × Clear all
NCT05901649 2026-05-08

ArtemisPRO

Janssen-Cilag Ltd.

Active not recruiting
504 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06991556 2026-05-01

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Novartis

Phase 2 Recruiting
150 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06874114 2026-04-13

RE-ENGAGE

Bayer

Active not recruiting
700 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT02799602 2025-12-04

ARASENS

Bayer

Phase 3 Completed
1,306 enrolled 25 charts 2 FDA
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06498921 2024-10-24

BELBEQA

Bayer

Completed
106 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡